Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens

Taispeáin leaganacha eile (1)

Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian adenoviruses do not suffer from the same drawbacks. We have con...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Antrobus, R, Coughlan, L, Berthoud, T, Dicks, MD, Hill, A, Lambe, T, Gilbert, S
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Nature Publishing Group 2014

Míreanna comhchosúla

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
de réir: Antrobus, R, et al.
Foilsithe / Cruthaithe: (2014)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
de réir: Folegatti, P, et al.
Foilsithe / Cruthaithe: (2019)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
de réir: Pedro M. Folegatti, et al.
Foilsithe / Cruthaithe: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
de réir: Zhang, C, et al.
Foilsithe / Cruthaithe: (2023)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
de réir: Cheng Zhang, et al.
Foilsithe / Cruthaithe: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
de réir: Adam Berg, et al.
Foilsithe / Cruthaithe: (2021-10-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
de réir: Dicks, M, et al.
Foilsithe / Cruthaithe: (2015)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
de réir: Charlotte Davis, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
de réir: Ashley C. Beavis, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
de réir: O'Hara, G, et al.
Foilsithe / Cruthaithe: (2012)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
de réir: Hermosilla, E, et al.
Foilsithe / Cruthaithe: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
de réir: Eduardo Hermosilla, et al.
Foilsithe / Cruthaithe: (2022-03-01)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
de réir: Sharpe, HR, et al.
Foilsithe / Cruthaithe: (2022)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
de réir: Jinnam Kim, et al.
Foilsithe / Cruthaithe: (2023-04-01)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
de réir: Tanie Natung, et al.
Foilsithe / Cruthaithe: (2023-01-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
de réir: Hannah R. Sharpe, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
de réir: Anupa Mary Job, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
de réir: Ogbe, A, et al.
Foilsithe / Cruthaithe: (2022)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
de réir: Moreira Folegatti, P
Foilsithe / Cruthaithe: (2021)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
de réir: Bas de Laat, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
de réir: Rujittika Mungmunpuntipantip, et al.
Foilsithe / Cruthaithe: (2021-11-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
de réir: Ane Ogbe, et al.
Foilsithe / Cruthaithe: (2022-04-01)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
de réir: Alharbi, N, et al.
Foilsithe / Cruthaithe: (2017)

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
de réir: Stedman, A, et al.
Foilsithe / Cruthaithe: (2019)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
de réir: Simone Barocci, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
de réir: Alharbi, N, et al.
Foilsithe / Cruthaithe: (2019)

Simian adenoviruses as vaccine vectors
de réir: Morris, S, et al.
Foilsithe / Cruthaithe: (2016)

Simian adenoviruses as vaccine vectors
de réir: Morris, S, et al.
Foilsithe / Cruthaithe: (2016)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
de réir: Giorgio Berlot, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
de réir: Lea Krutzke, et al.
Foilsithe / Cruthaithe: (2022-07-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
de réir: Tamara Garibashvili, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
de réir: Jennifer Serwanga, et al.
Foilsithe / Cruthaithe: (2024-01-01)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
de réir: Ewer, K, et al.
Foilsithe / Cruthaithe: (2020)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
de réir: Marchevsky, NG, et al.
Foilsithe / Cruthaithe: (2022)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
de réir: Edmund G.-T. Wee, et al.
Foilsithe / Cruthaithe: (2024-08-01)

ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys
de réir: Neeltje van Doremalen, et al.
Foilsithe / Cruthaithe: (2022-12-01)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
de réir: Natalie Gabrielle Marchevsky, et al.
Foilsithe / Cruthaithe: (2022-07-01)

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
de réir: Tao Ni, et al.
Foilsithe / Cruthaithe: (2023-10-01)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
de réir: Manabendra Basu, et al.
Foilsithe / Cruthaithe: (2024-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
de réir: Gerardo Casucci, et al.
Foilsithe / Cruthaithe: (2021-06-01)